PSA and Gleason Score Are Not Enough

For years, prostate cancer risk has been measured by PSA, Gleason score and stage, and diagnosis amd treatment protocols have remained much the same. However, that traditional assessment doesn’t provide all of the information needed to appropriately stratify prostate cancer risk and determine possible treatment options.

Managing Prostate Cancer

The management of clinically localized prostate cancer presents unique challenges for you and your patients due the highly variable and often nonaggressive nature of many prostate tumors. Increased insight into the aggressiveness of an individual patient’s prostate cancer can help you make better, more informed decisions about optimal prostate cancer management.

  • Clinical parameters, such as Gleason score, will continue to serve as the standard measurement for prostate cancer severity, but they do not measure the true hallmark of cancer – cell proliferation. Understanding how aggressively your patient’s tumor is growing adds critical, independent information that can help you and your patient make a more precise decision about treatment. In a prospective registry study of 305 patients, physicians changed their management of prostate cancer treatment based on the patients’ Prolaris result.

Using Molecular Diagnostics to Predict Prognosis and Guide Prostate Cancer Therapy

Prolaris® is a tissue-based molecular prognostic tool that was developed to aid you in determining prostate cancer aggressiveness, in conjunction with traditional clinical parameters such as Gleason score and PSA. Prolaris measures the expression level of genes involved with tumor proliferation to predict disease outcome, and it has been validated to predict prostate cancer-specific disease progression in several published clinical trials.1-6

By combining traditional risk factors with a molecular assessment of the aggressiveness of an individual patient’s prostate cancer, you have the information you need to make the most informed treatment decisions. Prolaris can assist you in identifying low or intermediate-risk patients who may be candidates for active surveillance, as well as patients who might be at potentially higher risk and would benefit from closer monitoring or more aggressive therapy. With the aid of molecular prognostic testing such as Prolaris, you can help reduce patient uncertainty and feel more confident about providing personalized patient care.

How To Use Prolaris In Your Practice

Prolaris testing is easy and appropriate for all patients diagnosed with localized prostate cancer.

Learn more about Prolaris testing

References

1. Centers for Disease Control and Prevention (CDC). Prostate cancer. Centers for Disease Control and Prevention website. http://www.cdc.gov/cancer/prostate/index.htm. Accessed August 10, 2012.

2. Cuzick J, Berney DM, Fisher G, et al; Transatlantic Prostate Group. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106(6):1-5.

3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer V1.1.2010.p. MS-2 www.nccn.org. Accessed April 2, 2010.

4. Thompson I, Leach RJ, Pollack BH, Naylor SL. Prostate cancer and prostate specific antigen: the more we know, the less we understand. J Natl Cancer Inst. 2003;95:1027-28.

5. Cuzick J, Berney DM, Fisher G, et al; Transatlantic Prostate Group. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106(6):1-5.

6. Data on file. Salt Lake City, UT: Myriad Genetic Laboratories, Inc.; 2011.